<DOC>
	<DOCNO>NCT01435044</DOCNO>
	<brief_summary>This study design assess safety efficacy multiple interferon-free treatment regimen sofosbuvir ( Sovaldiâ„¢ ; GS-7977 ; PSI-7977 ) GS-0938 ( PSI-352938 ) alone combination , without ribavirin ( RBV ) . Each regimen evaluate 12 24 week identify optimal duration therapy maximize benefit ( sustain virologic response [ SVR ] ) versus risk ( safety resistance ) .</brief_summary>
	<brief_title>Safety Study Regimens Sofosbuvir , GS-0938 , Ribavirin Patients With Chronic Hepatitis C Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Chronic HCVinfection Naive HCV antiviral treatment Otherwise healthy patient Positive test Screening HBsAg , antiHBc IgM Ab , antiHIV Ab History clinically significant chronic liver disease Medical history investigator considers patient unsuitable study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatitis C</keyword>
	<keyword>Chronic</keyword>
	<keyword>HCV</keyword>
</DOC>